Tagamet HB pricing to be lower than Pepcid AC per dose, SmithKline says.
This article was originally published in The Tan Sheet
Executive Summary
TAGAMET HB TO BE PRICED BETWEEN PEPCID AC AND MYLANTA on a per dose basis, SmithKline Beecham Consumer Healthcare-North America President Jack Ziegler said during a June 20 teleconference announcing FDA's approval of the new OTC drug. "Our expectation is that the consumer will find Tagamet pricing...lower than Pepcid on a per dose basis," but higher than Maalox and Mylanta, Ziegler said. SmithKline's OTC cimetidine was cleared by FDA on June 19 for symptomatic relief of heartburn, acid indigestion and sour stomach.